Tedor Pharma, Inc.
Tedor Pharma is a privately held US-based CDMO specializing in oral solid dosage form development and manufacturing, serving virtual pharma, generic, and biotech clients from its FDA-registered, DEA-licensed facility in Cumberland, Rhode Island.
- Company typePrivate
- Founded2001
- HeadquartersCumberland, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Tedor Pharma, Inc. does
Tedor Pharma, Inc., doing business as Tedor Pharma Services and TEDOR Pharma, is a privately held US-based contract development and manufacturing organization (CDMO) founded in 2001 and headquartered in Cumberland, Rhode Island. The company provides end-to-end services for oral solid dosage form pharmaceuticals, organized around four integrated service lines: formulation and process development, GMP analytical services, clinical trial supply services, and solid dose commercial manufacturing. Its purpose-built Cumberland facility is FDA registered and inspected, DEA licensed to manufacture controlled substances schedules II through V, and houses both pilot and commercial-scale equipment to support seamless scale-up. The firm focuses on difficult-to-formulate products, including poorly soluble APIs, high-potency compounds, multi-API combinations, and modified/extended-release formulations.
Tedor generates revenue through project-based quoting on multi-year contracts with pharmaceutical clients, priced per engagement rather than on disclosed unit rates. Its customer base spans virtual pharma companies that lack internal manufacturing, generic pharmaceutical developers pursuing ANDA and 505(b)(2) pathways, and innovator/biotech firms needing specialized solid dose capabilities. The go-to-market is direct enterprise sales supported by content marketing, industry event participation (including CPHI Milan 2026 and Mass Bio), and email nurture. The company positions itself as a smaller, more agile alternative to larger CDMOs, emphasizing a Quality by Design milestone-based project management process, transparent communication, and regulatory credentials for controlled substances.
Leadership is led by CEO Laura Iorio, who also serves on the Board of Directors, with senior hires including a CFO/EVP and a Director of Business Development that signal a gradual move toward more institutional governance. The company is privately held with no disclosed external investors, parent company, or funding rounds, and ownership and revenue are not publicly disclosed.
Tedor Pharma, Inc. firmographics
Firmographics- Name
- Tedor Pharma, Inc.
- Legal name
- Tedor Pharma, Inc.
- Website
- https://tedorpharma.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tedor Pharma is a privately held US-based CDMO specializing in oral solid dosage form development and manufacturing, serving virtual pharma, generic, and biotech clients from its FDA-registered, DEA-licensed facility in Cumberland, Rhode Island.
- Ownership category
- akta.pro rank
Tedor Pharma, Inc. industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Tedor Pharma, Inc. is headquartered
LocationHeadquarters
- HQ city
- Cumberland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Tedor Pharma, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: Tedor Pharma generates revenue through providing contract development and manufacturing services for pharmaceutical companies. Services are priced on a project basis with detailed quotes provided for each engagement. Revenue comes from formulation development, analytical services, clinical trial supply, and commercial manufacturing of solid dosage drug products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for pharmaceutical development and manufacturing services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Tedor Pharma, Inc. product offering
Product offeringCore offering
Tedor Pharma, Inc. operates as a contract development and manufacturing organization (CDMO) providing end-to-end pharmaceutical outsourcing services focused on oral solid dosage forms. The company offers four integrated service lines: formulation and process development, GMP analytical services, clinical trial supply services, and solid dose commercial manufacturing. It supports small molecule drug products from clinical Phase II through commercialization, including controlled substances (DEA schedules II-V), high-potency products, and modified-release formulations.
Product overview
Tedor Pharma Services is a contract development and manufacturing organization (CDMO) offering a unified platform of pharmaceutical services focused on oral solid dosage forms. The company provides an integrated service portfolio comprising Formulation & Process Development, Analytical Services, Clinical Trial Supply Services, and Solid Dose Commercial Manufacturing. These four service lines work together to deliver end-to-end outsourcing solutions, guiding small molecule drug products from IND/NDA/ANDA development through clinical trial supply to commercial-scale manufacturing, with specialized capabilities in controlled substances, high-potency products, and modified-release formulations.
Differentiator
Problem solved
Functional benefit
Products and services
- Formulation & Process Development Comprehensive formulation development and process optimization services for solid dosage forms, including tablets, capsules, modified-release products, and specialized delivery platforms, supporting clients from early clinical phases through commercial scale-up.
- Analytical Services GMP-compliant analytical testing services including method development, validation, transfer, stability-indicating assays, and quality assurance support from pre-formulation through commercialization.
- Clinical Trial Supply Services End-to-end clinical trial support including investigational drug product manufacturing, placebo manufacturing, clinical packaging and labeling, regulatory submission support, and logistics management for phases I-IV trials.
- Solid Dose Commercial Manufacturing GMP commercial manufacturing of oral solid dosage pharmaceuticals at clinical through large-scale commercial production volumes, including controlled substances, high-potency products, and modified-release formulations.
Quantifiable outcome
- Development costs and times can potentially be reduced by 25% and 50% respectively when outsourcing is executed properly with the right partners
Companies that use Tedor Pharma, Inc.
Customer profileSegments3 records
Ideal customer profiles3 records
Tedor Pharma, Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Tedor Pharma, Inc. partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights4 records
Tedor Pharma, Inc. competitors and assessment
Company assessmentRegional players
- Aenova Group: European-headquartered CDMO with solid dose formulation and commercial manufacturing. Operates in adjacent geography but offers similar service capabilities, providing a useful benchmark on European competition.
Direct peers
- Quotient Sciences: CDMO specializing in formulation development and clinical trial manufacturing for small molecule drugs; comparable scale and customer-mix overlap with Tedor.
- Cambrex: Small-molecule API and drug product CDMO with strong solid-oral-dose capabilities. Comparable in core technology emphasis though larger in scale than Tedor.
- Halo Pharma: Mid-market solid-dose CDMO providing formulation development and commercial manufacturing services. Directly comparable in service mix, scale, and customer segments.
- PCI Pharma Services: Global CDMO with significant clinical trial supply, packaging, and commercial manufacturing offerings for solid dose products — competes with Tedor across the clinical-to-commercial continuum.
- Alcami Corporation: US-based mid-sized CDMO offering formulation, analytical, and commercial manufacturing for oral solid dosage forms. Comparable in size and customer base to Tedor, with overlapping virtual pharma and biotech clients.
- Piramal Pharma Solutions: Global CDMO with dedicated oral solid dose capabilities serving biotech and generic customers. Provides formulation development through commercial manufacturing — directly overlapping Tedor's service portfolio.
- Metrics Contract Services: Specialized solid-dose contract manufacturer with strong generic-pharma focus and analytical development capabilities, serving a similar biotech/generic customer base.
Broad incumbents
- Patheon (Thermo Fisher Scientific): Global pharma services platform within Thermo Fisher providing formulation, analytical, clinical supply, and commercial manufacturing across multiple dosage forms. Larger incumbent competing in the same outsourced services category.
- Catalent: One of the largest global CDMOs with broad oral solid dose, softgel, and biologics capabilities. While much larger and broader than Tedor, it competes for the same biotech/pharma outsourcing dollars.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Tedor Pharma, Inc. social profiles
Digital presenceTedor Pharma, Inc. compliance and trust
Trust signalCompliance4 records
Tedor Pharma, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tedor Pharma, Inc. leadership team
Management profileNumber of profiles
Profiles5 records
Tedor Pharma, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tedor Pharma, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tedor Pharma, Inc.
What does Tedor Pharma, Inc. do?
Tedor Pharma, Inc. operates as a contract development and manufacturing organization (CDMO) providing end-to-end pharmaceutical outsourcing services focused on oral solid dosage forms. The company offers four integrated service lines: formulation and process development, GMP analytical services, clinical trial supply services, and solid dose commercial manufacturing. It supports small molecule drug products from clinical Phase II through commercialization, including controlled substances (DEA schedules II-V), high-potency products, and modified-release formulations.
Is Tedor Pharma, Inc. a public or private company?
Tedor Pharma, Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Tedor Pharma, Inc. founded?
Tedor Pharma, Inc. was founded in 2001. It employs 11 to 50 people.
Where is Tedor Pharma, Inc. based?
Tedor Pharma, Inc. is headquartered in Cumberland, United States, in the North America region.
How does Tedor Pharma, Inc. make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are Tedor Pharma, Inc.'s main competitors?
Aenova Group is listed as a regional player. Direct peers are Quotient Sciences, Cambrex, Halo Pharma, PCI Pharma Services, Alcami Corporation, Piramal Pharma Solutions and Metrics Contract Services. Broad incumbents are Patheon (Thermo Fisher Scientific) and Catalent.
Does Tedor Pharma, Inc. have an API?
No public API is recorded for Tedor Pharma, Inc..
What industry is Tedor Pharma, Inc. in?
Tedor Pharma, Inc.'s product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.